FLT4 and hypertrophic cardiomyopathy: However, a recent study also showed that the activation of the VEGF-C/VEGFR-3 axis prevented hypertrophic heart to heart failure (HF) and highlighted the selective stimulation of cardiac lymphangiogenesis as a potential treatment for hypertrophic cardiomyopathy (113).